<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129388</url>
  </required_header>
  <id_info>
    <org_study_id>INT11166</org_study_id>
    <nct_id>NCT01129388</nct_id>
  </id_info>
  <brief_title>Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects</brief_title>
  <official_title>A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given With Omeprazole 80 mg/Day (12 Hours Apart on the Same Days) in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on
           Adenosine diphosphate (ADP)-induced platelet aggregation when given either alone in the
           morning, or in association with omeprazole 80 mg/day in the evening at a 12-hours
           interval in healthy male and female subjects

      Secondary Objectives:

        -  Compare the pharmacokinetic profiles of clopidogrel and its active metabolite when
           clopidogrel is given either alone alone in the morning, or in association with
           omeprazole in the evening at a 12-hours interval
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per subjects is 8-9 weeks broken down as follows:

        -  Screening: 2 to 21 days before the first dosing

        -  Period clopidogrel/placebo: 7 days including 5 days treatment

        -  Period clopidogrel/placebo + omeprazole: 12 days including 10 days treatment

        -  Washout between periods: at least 14 days period after last dosing respect to
           clopidogrel treatment

        -  End of study: at 7 to 10 days after the last dosing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by Adenosine diphosphate (ADP) 5µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by ADP 20µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Index - Vasodilatator-stimulated phosphoprotein test (PRI - VASP) after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel pharmacokinetic parameters (maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUC0-24)) after 5 days treatment</measure>
    <time_frame>Up to 24 hours postdose on Day 5 for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel active metabolite pharmacokinetic parameters (Cmax and AUC0-24) after 5 days treatment</measure>
    <time_frame>Up to 24 hours postdose on Day 5 for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group clopidogrel - clopidogrel + omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions
Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily
Period 2:
Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily
Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group placebo - placebo + omeprazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1:
Day 1: placebo loading dose in the morning under fasted conditions
Day 2 to Day 5: placebo in the morning under fasted conditions, once daily
Period 2:
Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily
Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group clopidogrel + omeprazole - clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily
Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily
Period 2:
Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions
Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group placebo + omeprazole placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1:
Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner
Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily
Period 2:
Day 1: placebo loading dose in the morning under fasted conditions
Day 2 to Day 5: placebo in the morning under fasted conditions, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Group clopidogrel - clopidogrel + omeprazole</arm_group_label>
    <arm_group_label>Group clopidogrel + omeprazole - clopidogrel</arm_group_label>
    <other_name>SR25990</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: matching tablet
Route of administration: oral</description>
    <arm_group_label>Group placebo - placebo + omeprazole</arm_group_label>
    <arm_group_label>Group placebo + omeprazole placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>Pharmaceutical form: delayed-release capsule
Route of administration:oral</description>
    <arm_group_label>Group clopidogrel - clopidogrel + omeprazole</arm_group_label>
    <arm_group_label>Group placebo - placebo + omeprazole</arm_group_label>
    <arm_group_label>Group clopidogrel + omeprazole - clopidogrel</arm_group_label>
    <arm_group_label>Group placebo + omeprazole placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subject,

          -  as determined by medical history, physical examination including vital signs and
             clinical laboratory tests.

          -  with a body weight between 50 kg and 95 kg if male, between 40 kg and 85 kg if female,
             and with a Body Mass Index (BMI) between 18 and 30 kg/m²

        Exclusion Criteria:

          -  Evidence of inherited disorder of coagulation/hemostasis functions

          -  Smoking more than 5 cigarettes or equivalent per day

          -  Abnormal hemostasis screen

          -  Unability to abstain from intake of any drug affecting hemostasis throughout the whole
             study duration

          -  Any contraindication to clopidogrel and/or omeprazole

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Clinical Development Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65-74. doi: 10.1038/clpt.2010.219. Epub 2010 Sep 15.</citation>
    <PMID>20844485</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

